Literature DB >> 21400519

Prognostic significance of HLA class I expression in Ewing's sarcoma family of tumors.

Hiroki Yabe1, Tomohide Tsukahara, Satoshi Kawaguchi, Takuro Wada, Toshihiko Torigoe, Noriyuki Sato, Chihiro Terai, Masaya Aoki, Shigemichi Hirose, Hideo Morioka, Hiroo Yabe.   

Abstract

BACKGROUND: Ewing's sarcoma family of tumors (ESFT) is one of the most malignant groups of tumors in young people. Human leukocyte antigen (HLA) class I displays endogenously processed peptides to CD8+ T lymphocytes and has a key role for host immune surveillance. In ESFT, the investigation concerning both HLA class I expression and T-cell infiltration has yet to be reported.
METHODS: Biopsy specimens from 28 ESFT patients were evaluated by immunohistochemistry with the anti-HLA class I monoclonal antibody (mAb) EMR8-5 and anti-CD8 mAb, respectively.
RESULTS: Expression of HLA class I was negative in 10 tumors and down-regulated in 22 tumors. The status of CD8+ T cell infiltration was closely associated with the expression levels of HLA class I. ESFT patients with down-regulated or negative expression of HLA class I showed significantly poorer survival than the rest of the patients.
CONCLUSIONS: Our results suggested that CD8+ T cell-mediated immune response restricted by HLA class I might play an important role in immune surveillance of ESFT, and we revealed for the first time that the status of HLA class I expression affects the survival of the patients with ESFT.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21400519     DOI: 10.1002/jso.21829

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  16 in total

1.  EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors.

Authors:  Christopher H Evans; Fangjun Liu; Ryan M Porter; Regina P O'Sullivan; Taha Merghoub; Elaine P Lunsford; Kyle Robichaud; Frans Van Valen; Stephen L Lessnick; Mark C Gebhardt; James W Wells
Journal:  Clin Cancer Res       Date:  2012-08-09       Impact factor: 12.531

Review 2.  Understanding tumor heterogeneity as functional compartments--superorganisms revisited.

Authors:  Thomas G P Grunewald; Saskia M Herbst; Jürgen Heinze; Stefan Burdach
Journal:  J Transl Med       Date:  2011-05-27       Impact factor: 5.531

3.  Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion.

Authors:  Sabine Heitzeneder; Elena Sotillo; Jack F Shern; Sivasish Sindiri; Peng Xu; Robert Jones; Michael Pollak; Pernille R Noer; Julie Lorette; Ladan Fazli; Anya Alag; Paul Meltzer; Ching Lau; Cheryl A Conover; Claus Oxvig; Poul H Sorensen; John M Maris; Javed Khan; Crystal L Mackall
Journal:  J Natl Cancer Inst       Date:  2019-09-01       Impact factor: 13.506

Review 4.  Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.

Authors:  Michael J Nathenson; Anthony P Conley; Edward Sausville
Journal:  Oncologist       Date:  2017-09-21

5.  Associations of PD-L1, PD-L2, and HLA class I expression with responses to immunotherapy in patients with advanced sarcoma: post hoc analysis of a phase 1/2 trial.

Authors:  S Miwa; T Nojima; A A Alomesen; H Ikeda; N Yamamoto; H Nishida; K Hayashi; A Takeuchi; K Igarashi; T Higuchi; H Yonezawa; Y Araki; S Morinaga; Y Asano; H Tsuchiya
Journal:  Clin Transl Oncol       Date:  2021-02-26       Impact factor: 3.405

6.  Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.

Authors:  Deepa Kolaseri Krishnadas; Lei Bao; Fanqi Bai; Satheesh Cheeyancheri Chencheri; Kenneth Lucas
Journal:  Tumour Biol       Date:  2014-03-02

Review 7.  Potential of human γδ T cells for immunotherapy of osteosarcoma.

Authors:  Zhaoxu Li
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

8.  APLP2 regulates the expression of MHC class I molecules on irradiated Ewing's sarcoma cells.

Authors:  Haley L Peters; Ying Yan; Joyce C Solheim
Journal:  Oncoimmunology       Date:  2013-10-08       Impact factor: 8.110

9.  Prognostic value of HLA class I expression in patients with colorectal cancer.

Authors:  Yuji Iwayama; Tetsuhiro Tsuruma; Toru Mizuguchi; Tomohisa Furuhata; Nobuhiko Toyota; Masayuki Matsumura; Toshihiko Torigoe; Noriyuki Sato; Koichi Hirata
Journal:  World J Surg Oncol       Date:  2015-02-12       Impact factor: 2.754

10.  Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma.

Authors:  Maurizio Ghisoli; Minal Barve; Reva Schneider; Robert Mennel; Carl Lenarsky; Gladice Wallraven; Beena O Pappen; John LaNoue; Padmasini Kumar; Derek Nemunaitis; Alyssa Roth; James Nemunaitis; Sam Whiting; Neil Senzer; Frederick A Fletcher; John Nemunaitis
Journal:  Mol Ther       Date:  2015-03-19       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.